Pulmonary sclerosing pneumocytoma may be an under-recognized pulmonary manifestation of the phosphatase and tensin homolog deleted on chromosome 10 (PTEN) hamartoma tumour syndrome
European Journal of Case Reports in Internal Medicine · 21.10.2026 · 13 (11)
DOI: 10.12890/2026_007500 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Case Reports in Internal Medicine, online erschienen am 21.10.2026. Verfasst von Arwa Alghamdi und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, King Saud University, Riyadh, Saudi Arabia. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
Pulmonary sclerosing pneumocytoma (PSP) is a rare, benign neoplasm driven by somatic AKT1 mutations that activate the PI3K/AKT/mTOR pathway. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) hamartoma tumour syndrome (PHTS) results from germline pathogenic variants affecting the tumour suppressor gene PTEN, which regulates the same pathway. Although PSP is not an established manifestation of PHTS a small number of reports have suggested a possible association. Case description: A 23-year- old Saudi woman presented with an incidental 9 mm pulmonary nodule detected during imaging. Her history included bilateral benign thyroid nodules, a left breast nodule (BI-RADS 3) and a venolymphatic malformation. Family history was significant for maternal breast cancer, a sister with diffuse lipomatosis, and a brother with autism spectrum disorder. Video-assisted thoracoscopic surgery (VATS) wedge resection was performed; histopathology and immunohistochemistry confirmed PSP. Chromosomal microarray analysis revealed a pathogenic germline deletion at 10q23.31 encompassing PTEN, confirming the diagnosis of PHTS.
Conclusion
This case adds molecularly confirmed adult evidence to the limited literature describing PSP in patients with PTEN alterations. The coexistence of germline PTEN loss and a tumour characterized by PI3K/AKT/mTOR pathway activation provides a biologically plausible basis for further investigation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- College of Medicine, King Saud University, Riyadh, Saudi Arabia.
- Department of Surgery (Thoracic Surgery Division), King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia.
- Department of Pathology (Histopathology Division), College of Medicine, King Saud University, Riyadh, Saudi Arabia.
- Department of Surgery (Thoracic Surgery Division), College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Zitieren
APA
Alghamdi, A., Alotaibi, A., Aljohani, A., Almaymuni, A., Althakfi, W., & Hajjar, W. M. (2026). Pulmonary sclerosing pneumocytoma may be an under-recognized pulmonary manifestation of the phosphatase and tensin homolog deleted on chromosome 10 (PTEN) hamartoma tumour syndrome. European Journal of Case Reports in Internal Medicine, 13(11). https://doi.org/10.12890/2026_007500
Vancouver
Alghamdi A, Alotaibi A, Aljohani A, Almaymuni A, Althakfi W, Hajjar WM. Pulmonary sclerosing pneumocytoma may be an under-recognized pulmonary manifestation of the phosphatase and tensin homolog deleted on chromosome 10 (PTEN) hamartoma tumour syndrome. European Journal of Case Reports in Internal Medicine. 2026;13(11). doi:10.12890/2026_007500
BibTeX
@article{Alghamdi2026,
author = {Alghamdi, Arwa and Alotaibi, Amani and Aljohani, Ajwan and Almaymuni, Adel and Althakfi, Wajd and Hajjar, Waseem M},
title = {Pulmonary sclerosing pneumocytoma may be an under-recognized pulmonary manifestation of the phosphatase and tensin homolog deleted on chromosome 10 (PTEN) hamartoma tumour syndrome},
journal = {European Journal of Case Reports in Internal Medicine},
year = {2026},
volume = {13},
number = {11},
doi = {10.12890/2026_007500}
}
EUVIMED